2023-03-06 10:53:35 ET
- Therapeutic Solutions International ( OTCPK:TSOI ) said it plans to start a 10-patient proof-of-concept trial via Res Nova Bio subsidiary aimed at showing the ability of FloraStilbene to stimulate the immune system in patients with advanced breast cancer.
- The company noted that it received a patent on using pterostilbene and pterostilbene compositions for synergy with cancer immunotherapy.
- TSOI noted the creation of a novel immune stimulatory adjuvant combining pterostilbene with RU-486 called FloraStilbene.
- "FloraStilbene represents a non-toxic approach to overcoming breast cancer induced immune suppression, which acts as a significant barrier to efficacy of oncology immunotherapy," said Chief Medical Officer James Veltmeyer.
For further details see:
Therapeutic Solutions plans to start breast cancer trial using FloraStilbene